Medicare and Medicaid
Our work in Medicare and Medicaid
-
Opinion: I’m a Doctor in East L.A. and Beverly Hills. I Want to Treat Obesity the Same Way in Both Places
Use of newer anti-obesity medications in any part of town can provide true benefit even if lifestyle changes are harder to implement.
Categorized in -
The CBO Report on Medicare and Anti-Obesity Medications Should Not Be the Final Word
The highly anticipated report contains clues on how Congress may come to a different view on medications like Wegovy and Zepbound.
Categorized in -
How the Next President Should Reform Medicare
If left alone, Medicare Advantage will increasingly push overall costs in Medicare into unsustainable territory. Needed reforms can be phased in over a period of years.
Categorized in -
The Future of Medicare’s Coverage with Evidence Development Policy
Join the USC Schaeffer Center in partnership with the Tufts Center for Evaluation of Value and Risk in Health and the Stanford Byers Center for Biodesign, for a conversation on the future of CED.
Categorized in -
Comments to Representatives DeGette and Bucshon on Building on the Successes of 21st Century Cures
Schaeffer Center experts provided comments to lawmakers on additional measures for enhancing or improving the effectiveness of the 21st Century Cures Act.
Categorized in -
Growing Divergence Between Medicare Advantage Plan Bids and Payments to Plans
While risk-adjusted Medicare Advantage bids have decreased compared with risk-adjusted traditional Medicare spending, total payments to MA plans have risen partly because of the growing impact of payment adjustments.
Categorized in -
Study: Exploding Popularity of Ozempic and Wegovy Among Privately Insured Patients May Worsen Disparities
Publicly insured individuals who are most likely to benefit from new diabetes and obesity drugs are less likely to get them than those with private insurance.
Categorized in -
Comments to CMS on Transcatheter Tricuspid Valve Replacement (TTVR) and Broader CED Policy Considerations
Schaeffer Center experts provided comments to CMS on issues with how Coverage with Evidence Determination policy is applied.
Categorized in -
Estimating Overpayments to MA Plans: MedPAC Critics Get It Wrong
Why many of the key assertions in a recent Forefront article challenging the MedPAC’s estimate that favorable selection and upcoding increase payments to Medicare Advantage (MA) plans in 2024 by $83 billion are wrong.
Categorized in -
Access to New Alzheimer’s Treatments Bogged Down by Medicare Policy
There are now two Alzheimer’s treatments with significant clinical benefit. It’s not clear how quickly patients will be able to benefit.
Categorized in